How to buy MorphoSys stock

MorphoSys AG is a biotechnology business based in the US. MorphoSys shares (MOR) are listed on the NASDAQ and all prices are listed in US Dollars. MorphoSys employs 615 staff and has a trailing 12-month revenue of around 0.00.

MorphoSys share price

Use our graph to track the performance of MOR stocks over time.

MorphoSys shares at a glance

• Key figures

Information last updated 2021-04-21.

52-week range	$21.27 - $35.73
50-day moving average	$23.12
200-day moving average	$26.59
Wall St. target price	$31.48
PE ratio	25.5074
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.89

Buy MorphoSys shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy MorphoSys stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of MorphoSys AG by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is MorphoSys under- or over-valued?

Valuing MorphoSys stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MorphoSys's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

MorphoSys's P/E ratio

MorphoSys's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, MorphoSys shares trade at around 26x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

MorphoSys's EBITDA

MorphoSys's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $38.7 million.

The EBITDA is a measure of a MorphoSys's overall financial performance and is widely used to measure a its profitability.

MorphoSys financials

Revenue TTM	$327.7 million
Operating margin TTM	10.37%
Gross profit TTM	$318.5 million
Return on assets TTM	1.97%
Return on equity TTM	19.27%
Profit margin	29.87%
Book value	$4.74
Market capitalisation	$3 billion

TTM: trailing 12 months

Shorting MorphoSys shares

There are currently 103,691 MorphoSys shares held short by investors – that's known as MorphoSys's "short interest". This figure is 55.3% down from 231,952 last month.

There are a few different ways that this level of interest in shorting MorphoSys shares can be evaluated.

MorphoSys's "short interest ratio" (SIR)

MorphoSys's "short interest ratio" (SIR) is the quantity of MorphoSys shares currently shorted divided by the average quantity of MorphoSys shares traded daily (recently around 117830.68181818). MorphoSys's SIR currently stands at 0.88. In other words for every 100,000 MorphoSys shares traded daily on the market, roughly 880 shares are currently held short.

However MorphoSys's short interest can also be evaluated against the total number of MorphoSys shares, or, against the total number of tradable MorphoSys shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MorphoSys's short interest could be expressed as 0% of the outstanding shares (for every 100,000 MorphoSys shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable MorphoSys shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against MorphoSys.

Find out more about how you can short MorphoSys stock.

MorphoSys share dividends

We're not expecting MorphoSys to pay a dividend over the next 12 months.

MorphoSys share price volatility

Over the last 12 months, MorphoSys's shares have ranged in value from as little as $21.27 up to $35.73. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MorphoSys's is 0.7957. This would suggest that MorphoSys's shares are less volatile than average (for this exchange).

MorphoSys overview

MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Frequently asked questions

• What percentage of MorphoSys is owned by institutions?

  Currently 2.598% of MorphoSys shares are held by institutions.

• How many people work for MorphoSys?

  Latest data suggests 615 work at MorphoSys.

• When does the fiscal year end for MorphoSys?

  MorphoSys's fiscal year ends in December.

• Where is MorphoSys based?

  MorphoSys's address is: Semmelweisstrasse 7, Planegg, Germany, 82152

• What is MorphoSys's ISIN number?

  MorphoSys's international securities identification number is: US6177602025

• What is MorphoSys's CUSIP number?

  MorphoSys's Committee on Uniform Securities Identification Procedures number is: 617760202